Products for Research Use Only
RegisterLogin

Braftide

CAT: 0804-HY-P10436-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P10436-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAFG469A with IC50 of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells (EC50 is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence. Braftide can be used for cancer research[1][2].
CAS Number
2411851-64-2
UNSPSC
12352209
Target
Raf
Type
Peptides
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/braftide.html
Purity
99.68
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CNC=N1)C(N[C@@H](C(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCSC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@H](O)C)N
Molecular Formula
C57H94N16O13S
Molecular Weight
1243.52
References & Citations
[1]Gunderwala AY, et al., Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF. ACS Chem Biol. 2019 Jul 19;14 (7) :1471-1480. |[2]Yu A. Mechanistic Investigations of a Novel BRAF Regulatory Switch and Braftide, an Allosteric Peptide Inhibitor of BRAF[D]. Rowan University, 2023.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported

Alternative Products

CatalogName
CRB1001646-01Braftide
GTR19144459-01Tat-braftide
CRB1001646-01Braftide - (Cancer Peptides)

Popular Products